Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Equinor ASA (EQNR) vs Heron Therapeutics Inc (HRTX) Price & Performance

Equinor ASATrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Equinor ASA vs Heron Therapeutics Inc — how do they compare? Equinor ASA trades at $40.98 (market cap $97.58B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: Equinor ASA is far larger — about 1587.4× Heron Therapeutics Inc's market cap, and Equinor ASA pays a 3.81% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

EQNRHRTX
Market Cap
$97.58B$61.47M
Sector
EnergyHealth
52-Week High
$42.40$1.49
52-Week Low
$22.41$0.32
Enterprise Value
$106.28B$168.21M
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Equinor ASA

Equinor (EQNR) trades at $40.92, down slightly by 0.17% on the day, with strong technical momentum showing a bullish moving average signal. The company delivered mixed Q2 2026 earnings with a revenue beat but EPS miss, while maintaining robust cash flow generation and shareholder returns through dividends and buybacks. Recent news highlights strong quarterly performance driven by higher energy prices and production growth.

EQNR presents a compelling value case with attractive valuation multiples (P/E 11.09, EV/EBITDA 2.3) and solid profitability metrics (ROE 21.32%). However, declining profit margins from 19.29% in 2022 to 4.76% in 2025 and analyst caution (56.53% hold rating) suggest balanced risk-reward. The stock offers income potential with consistent dividends amid energy market volatility.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Equinor ASA

Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.

Read more on EQNR

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX